Abstract
By-products of complement activation and complement regulatory proteins are increasingly recognized to play an important pathogenic role in a variety of vascular diseases including atherosclerosis, ischemia and reperfusion injury, hyperacute graft rejection, vasculitis, and the vascular complications of human diabetes. “Self” damage by autologous complement is mediated by activation products of the complement cascades or by direct insertion of the membrane attack complex (MAC) into cell membranes. Specifically, insertion of MAC complexes into endothelial cells results in the release of an array of growth factors and cytokines that induces proliferation, inflammation and thrombosis in the vascular wall. This paper reviews complement and complement regulatory proteins with specific focus on the vasculature and vascular diseases; it highlights complement and its regulators as potential targets for the rational design of mechanismspecific drugs for the treatment of some of the most prevalent human diseases.
Keywords: Proteins, mechanismspecific, vasculitis, thrombosis, MAC complexes
Current Pharmaceutical Design
Title: Complement and Complement Regulatory Proteins as Potential Molecular Targets for Vascular Diseases
Volume: 10 Issue: 2
Author(s): Juan Acosta, Xuebin Qin and Jose Halperin
Affiliation:
Keywords: Proteins, mechanismspecific, vasculitis, thrombosis, MAC complexes
Abstract: By-products of complement activation and complement regulatory proteins are increasingly recognized to play an important pathogenic role in a variety of vascular diseases including atherosclerosis, ischemia and reperfusion injury, hyperacute graft rejection, vasculitis, and the vascular complications of human diabetes. “Self” damage by autologous complement is mediated by activation products of the complement cascades or by direct insertion of the membrane attack complex (MAC) into cell membranes. Specifically, insertion of MAC complexes into endothelial cells results in the release of an array of growth factors and cytokines that induces proliferation, inflammation and thrombosis in the vascular wall. This paper reviews complement and complement regulatory proteins with specific focus on the vasculature and vascular diseases; it highlights complement and its regulators as potential targets for the rational design of mechanismspecific drugs for the treatment of some of the most prevalent human diseases.
Export Options
About this article
Cite this article as:
Acosta Juan, Qin Xuebin and Halperin Jose, Complement and Complement Regulatory Proteins as Potential Molecular Targets for Vascular Diseases, Current Pharmaceutical Design 2004; 10 (2) . https://dx.doi.org/10.2174/1381612043453441
DOI https://dx.doi.org/10.2174/1381612043453441 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Current Research on Opioid Receptor Function
Current Drug Targets Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology Involvement of Orbital Structures in Rheumatic Disease
Current Rheumatology Reviews PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Current Pharmaceutical Design An Update on Autoinflammatory Diseases
Current Medicinal Chemistry Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Cardiovascular Disease in Juvenile Idiopathic Arthritis
Current Vascular Pharmacology Nitric Oxide is a Central Common Metabolite in Vascular Dysfunction Associated with Diseases of Human Pregnancy
Current Vascular Pharmacology Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design T Cell Receptor Bias in Humans
Current Immunology Reviews (Discontinued) Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Long Term Stability Evaluation of Prostacyclin Released from Biomedical Device through Turbiscan Lab Expert
Medicinal Chemistry Deciphering Supportive Treatment Strategies for Toxic Epidermal Necrolysis
Current Drug Safety Type I Interferon as a Target of Treatment in SLE
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor
Current Cardiology Reviews Thrombotic Thrombocytopenic Purpura, from the Perspectives of a Pediatrician
Current Pediatric Reviews Cardiovascular Magnetic Resonance for Evaluation of Heart Involvement in ANCA-Associated Vasculitis. A Luxury or a Valuable Diagnostic Tool?
Inflammation & Allergy - Drug Targets (Discontinued)